IL166312A0 - A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor - Google Patents
A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitorInfo
- Publication number
- IL166312A0 IL166312A0 IL16631203A IL16631203A IL166312A0 IL 166312 A0 IL166312 A0 IL 166312A0 IL 16631203 A IL16631203 A IL 16631203A IL 16631203 A IL16631203 A IL 16631203A IL 166312 A0 IL166312 A0 IL 166312A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- composition containing
- receptor antagonist
- acat inhibitor
- adp receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002209165 | 2002-07-18 | ||
| PCT/JP2003/009108 WO2004009119A1 (ja) | 2002-07-18 | 2003-07-17 | 動脈硬化症治療のための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL166312A0 true IL166312A0 (en) | 2006-01-15 |
Family
ID=30767676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16631203A IL166312A0 (en) | 2002-07-18 | 2003-07-17 | A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1555032A1 (xx) |
| KR (1) | KR20050025604A (xx) |
| CN (1) | CN1681533A (xx) |
| AU (1) | AU2003248077A1 (xx) |
| BR (1) | BR0312778A (xx) |
| CA (1) | CA2493384A1 (xx) |
| IL (1) | IL166312A0 (xx) |
| MX (1) | MXPA05000726A (xx) |
| NO (1) | NO20050877L (xx) |
| PL (1) | PL373383A1 (xx) |
| RU (1) | RU2005104432A (xx) |
| TW (1) | TW200407135A (xx) |
| WO (1) | WO2004009119A1 (xx) |
| ZA (1) | ZA200500431B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200600497A (en) * | 2001-02-02 | 2006-01-01 | Sankyo Co | Preparation of indoline derivative |
| MXPA05014086A (es) * | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias antiagregantes plaquetarios combinadas para su uso en el tratamiento y prevencion de eventos vasculares de origen isquemico. |
| KR101647842B1 (ko) * | 2006-12-07 | 2016-08-11 | 다이이찌 산쿄 가부시키가이샤 | 저장 안정성이 개선된 의약 조성물 |
| TWI482641B (zh) | 2006-12-07 | 2015-05-01 | Daiichi Sankyo Co Ltd | 含有低取代度羥丙基纖維素之醫藥組成物 |
| CN101594864B (zh) * | 2006-12-07 | 2012-04-18 | 第一三共株式会社 | 生产固体制剂的方法 |
| WO2008072534A1 (ja) * | 2006-12-07 | 2008-06-19 | Daiichi Sankyo Company, Limited | マンニトール又は乳糖を含有する固形製剤 |
| CN101594863B (zh) * | 2006-12-07 | 2011-12-07 | 第一三共株式会社 | 具有改进稳定性的涂膜制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62167791A (ja) * | 1986-01-20 | 1987-07-24 | Morinaga Milk Ind Co Ltd | 血小板凝集抑制剤 |
| DK0683789T3 (da) * | 1993-02-10 | 1998-02-09 | Astra Pharma Prod | N-alkyl-2-substituerede ATP-analoger |
| CN1097043C (zh) * | 1995-10-05 | 2002-12-25 | 京都药品工业株式会社 | 新的杂环衍生物及其医药用途 |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| DK1298132T3 (da) * | 2000-07-06 | 2007-03-12 | Sankyo Co | Hydropyridinderivatsyreadditionssalte |
-
2003
- 2003-07-17 PL PL03373383A patent/PL373383A1/xx not_active Application Discontinuation
- 2003-07-17 CN CNA038218216A patent/CN1681533A/zh active Pending
- 2003-07-17 EP EP03765315A patent/EP1555032A1/en not_active Withdrawn
- 2003-07-17 KR KR1020057000754A patent/KR20050025604A/ko not_active Withdrawn
- 2003-07-17 MX MXPA05000726A patent/MXPA05000726A/es unknown
- 2003-07-17 AU AU2003248077A patent/AU2003248077A1/en not_active Abandoned
- 2003-07-17 WO PCT/JP2003/009108 patent/WO2004009119A1/ja not_active Ceased
- 2003-07-17 RU RU2005104432/15A patent/RU2005104432A/ru not_active Application Discontinuation
- 2003-07-17 CA CA002493384A patent/CA2493384A1/en not_active Abandoned
- 2003-07-17 IL IL16631203A patent/IL166312A0/xx unknown
- 2003-07-17 BR BR0312778-8A patent/BR0312778A/pt not_active Application Discontinuation
- 2003-07-18 TW TW092119615A patent/TW200407135A/zh unknown
-
2005
- 2005-01-17 ZA ZA200500431A patent/ZA200500431B/xx unknown
- 2005-02-18 NO NO20050877A patent/NO20050877L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003248077A1 (en) | 2004-02-09 |
| CA2493384A1 (en) | 2004-01-29 |
| CN1681533A (zh) | 2005-10-12 |
| RU2005104432A (ru) | 2005-08-10 |
| KR20050025604A (ko) | 2005-03-14 |
| BR0312778A (pt) | 2005-05-03 |
| EP1555032A1 (en) | 2005-07-20 |
| MXPA05000726A (es) | 2005-04-08 |
| NO20050877L (no) | 2005-02-18 |
| WO2004009119A1 (ja) | 2004-01-29 |
| PL373383A1 (en) | 2005-08-22 |
| TW200407135A (en) | 2004-05-16 |
| ZA200500431B (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE394375T1 (de) | Zusammensetzung enthaltend einen tachykininrezeptor antagonisten und einen serotonin-wiederaufnahmehemmer | |
| IL169575A0 (en) | Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same | |
| IL201658A0 (en) | Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist | |
| IL166809A0 (en) | Pharmaceutical nati-tnf-alpha antibody formulation | |
| AU2003302603A8 (en) | Improved opioid pharmaceutical compositions | |
| EP1550657A4 (en) | AMINO COMPOUNDS AND THEIR USE | |
| IL164185A0 (en) | Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives | |
| IL165841A0 (en) | Mchir antagonists | |
| AU2003291103A8 (en) | Pharmaceutical composition | |
| AU2003288640A1 (en) | Benzamide inhibitors of the p2x7 receptor | |
| HUP0302382A3 (en) | Il-8 receptor antagonists and pharmaceutical compositions containing them | |
| IL158083A0 (en) | A PHARMACEUTICAL COMPOSITION CONTAINING AN Eg5 PROTEIN INHIBITOR | |
| AU2003250372A8 (en) | Pharmaceutical composition | |
| IL161997A (en) | Pharmaceutical composition comprising a 5ht1 receptor agonist | |
| ZA200602260B (en) | A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug | |
| IL164973A0 (en) | Peptide deformylase inhibitors | |
| HUP0302003A3 (en) | Il-8 receptor antagonists and pharmaceutical compositions containing them | |
| IL175292A0 (en) | Pharmaceutical composition, containing a beta-3- adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor | |
| IL166312A0 (en) | A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor | |
| HUP0302614A3 (en) | Il-8 receptor antagonists and pharmaceutical compositions containing them | |
| EP1541139A4 (en) | DRUG COMPOSITION WITH NF-KAPPA B HEMMER | |
| AU2003206014A8 (en) | Neuropeptide receptor and uses thereof | |
| AU2003296960A8 (en) | Peptide deformylase inhibitors | |
| AU2002359524A8 (en) | P2x7 receptor antagonists | |
| AU155083S (en) | Pharmaceutical packaging |